U.S. Patter and Trademark Office U.S. DePARTMENT OF COMMERCE.

U.S. Patter and Trademark Office U.S. DEPARTMENT OF COMMERCE.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless of continues and id-656 control of collection.

	Filing
INFORMATION DISCLOSURE	First N
STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	Art Un
( NOC IOI SUDIMISSION UNDER OF OTIC 1.33)	-

Application Number		09441140	
Filing Date		1999-11-16	
First Named Inventor Beka		SOLOMON	
Art Unit		1649	
Examiner Name S. Tu		mer	
Attorney Docket Number		SOLOMON1R	

					U.S.I	PATENTS				
Examiner Initial*	Cite No	Patent Number	Kind Code <sup>1</sup>	Issue D	late	Name of Pate of cited Docu	entee or Applicant ment	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1									
If you wis	n to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.			
			U.S.P	ATENT	APPLI	CATION PUBL	ICATIONS			
Examiner Initial*	Cite No Publication Number Kind Date Name of Patentee or Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear							
	1									
If you wis	h to a	I dd additional U.S. Publ	shed Ap	l plication	citation	n information p	lease click the Add	d butto	in.	
				FOREIG	SN PAT	ENT DOCUM	ENTS			
Examiner Cite Foreign Document Country Initial* No Number3 Country			Kind Code <sup>4</sup>	Publication Date	Name of Patentee Applicant of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear	TS		
	1									
If you wish	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	buttor	1	
			NON	I-PATE	IT LITE	RATURE DO	CUMENTS			
Examiner Initiatis* Cite (Not (Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T5			

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1,99)

plication Number		09441140
ing Date		1999-11-16
rst Named Inventor Beka		SOLOMON
t Unit		1649
aminer Name S. Tu		mer
torney Docket Number		SOLOMON1R

Examir	er Signa	ature	Date Considered		
			EXAMINER SIGNATURE		
If you v	vish to a	dd add	ditional non-patent literature document citation information please click the Add butte	on	
	3	VICK	KERS, JC., "A Vaccine Against Alzheimer's Disease: Developments to Date", Drugs Aging, 20	02, 19(7):487-494	
	2		LUSTIG, ES, et al., "Peripheral Markers and Diagnostic Criteria in Alzheimer's Disease: Critica rosci., 1994; 5:213-224	al Evaluations*, Rev	
	1	Co-pe there	pending U.S. application no 11/356,951, filed February 22, 2006, including all papers in the pri aof.	osecution history	

Fil

E) At

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> See Vint Codes of USPTO Patent Documents at ImmuNSTIG.00U or MPDF 901.04. 2 litter office that Immust the document, by the law-lawer code (WPO) Standard 57.3. 1 Per Uspensee patent for countert, the indication of the year of the region of the Emporer compress the samil number of the patent for impatent patent and the part of the patent of the pate

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09441140	
Filling Date		1999-11-16	
First Named Inventor Beka		SOLOMON	
Art Unit		1649	
xaminer Name S. Tu		imer	
Attorney Docket Numb	er	SOLOMON1R	

### CERTIFICATION STATEMENT

Diagra con				

That each item of information contained in the information disclosure statement was first cited in any communication
from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the
information disclosure statement. See 37 CFR 1.97(e)(1).

## OR

That no item of information contained in the information disclosure statement was clied in a communication from a foreign patient office in a counterpart foreign application, and, to be thousedge of the person spring the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to all yet making reasonable inquiry, no item of information contained in the information disclosure statement was known to any midroducid designated in 37 CPR 1,56(c) more than three morthly prior to the filting of the information disclosure

# See attached certification statement

X Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

#### None

# SIGNATURE A signature of the applicant or representative is required in accordance with CFR 1,33, 10,18. Please see CFR 1,4(d) for the

A signature of the applicant of representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Signature	/rlb/	Date (YYYY-MM-DD)	2007-03-16
Name/Print	Roger L. Browdy	Registration Number	25,618

This collection of information is required by 37 CFR 187 and 1.88. The information is required to obtain or resin a benefit by the public which is the field only be IMSPTO to process) an epitication. Confidentially is governed by 58 U.S. C. 22 and 37 ER. 1.4. This collection is estimated to late 1 hour to complete, including agithering, preparing and submitting the completed application from the IMSPTO. Time will vary depending upon the intrivial case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing his burden, should be sent to the Chief information Officer, U.S. Peters and Tradenter (Office, U.S. Department off Commency - D. Best 1493, Usearandia, V.2.2311-450, D. NOT SED, EEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Petents, P.O. Box 1450, Alexandria, V.2.2311-450.

#### Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-978) requires that you be given certain information in connection with your submission of the attached from resident to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 25 U.S.C. 2(b)(2); (2) turnishing of the information solicide is voluntary; and (3) the principal purpose for which the enformation is used by the U.S. Patient and Trademark Office and the principal purpose of which the enformation is used by the U.S. Patient and Trademark Office may not be able to process and/or saxinities you submission, which may result in termination of proceedings or abandoment of the application or expendition of the patient.

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (6 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
- A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
- A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an Individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
- A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
- A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
  may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
  to the Patent Cooperation Treaty.
- A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
  - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designer, during an inspection of records conducted by QSAs ap and for that server's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about involvious.
- 8. A record from this system of records may be chaddoned, as a routine suse, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patient pursuant to 35 U.S.C. 15. Further, a record may be disclosed, subject to the limitations of 37 CPR 1.14, as a routine use, to the public fifthe record was first in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patient.
  - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.